Investing.com - MustGrow Biologics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
MustGrow Biologics announced earnings per share of C$-0.03 on revenue of C$3.72K. Analysts polled by Investing.com anticipated EPS of C$-0.01 on revenue of C$0.00.
MustGrow Biologics shares are down 57% from the beginning of the year, still down 53.04% from its 52 week high of C$5.60 set on October 26, 2021. They are under-performing the Nasdaq which is down 24.67% from the start of the year.
MustGrow Biologics follows other major Healthcare sector earnings this month
MustGrow Biologics's report follows an earnings missed by Curaleaf on August 8, who reported EPS of C$-0.04 on revenue of C$337.55M, compared to forecasts EPS of C$-0.038 on revenue of C$333.81M.
Trulieve Cannabis had missed expectations on August 10 with second quarter EPS of C$-0.12 on revenue of C$320.3M, compared to forecast for EPS of C$-0.008 on revenue of C$321.64M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar